Please assess the completion status of the following clinical trial:

Trial Title: Intranasal Dexmedetomidine Premedication in Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children older than 5yrs and weighing more than 20kg , who are scheduled for ambulatory dental rehabilitation at Batson operating rooms.~* ASA classification 1 or 2~Exclusion Criteria~* Known allergy to midazolam, dexmedetomidine,morphine, fentanyl, sevoflurane and propofol.~* uncorrected congenital heart disease or history of cardiac arrhythmia,~* children at risk for airway obstruction (OSA or cranio facial syndrome),~* pregnant minors

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Midazolam (Type: ACTIVE_COMPARATOR): In M group, patients will be given oral midazolam 0.5mg/kg upto maximum dose of 15mg (5mg/ml parenteral preparation) mixed with flavored syrup as premedication
- Dexmedetomidine (Type: EXPERIMENTAL): In D group, patients will be given intranasal dexmedetomidine 2mcg/kg upto maximum dose of 100mcg prepared from 100mcg/ml parenteral preparation (Hospira R) . The drug will be administered using a intranasal mucosal administration device (LMA MAD NasalTM).

Based on this trial design, predict the completion outcome and termination type (if applicable).